Nasdaq:SNES
SenesTech, Inc.
A gene editing biotech firm leveraging proprietary platforms to advance therapeutic development in the pharmaceutical sector.
Key Metrics
Investment Thesis
Bull Case
SenesTech possesses a differentiated gene editing platform with significant unmet medical need potential in rare genetic disorders that could yield blockbuster therapies upon approval. The company has demonstrated consistent revenue expansion and reduced losses from -$9.7M to -$6.2M over the last three years, suggesting improving operational efficiency as the business scales.
Bear Case
The company faces an existential liquidity crunch with cash flow from operations of -$6.0M against only $1.3M in cash and equivalents, creating immediate pressure to issue more equity or debt. Persistent heavy losses and a massive retained earnings deficit make it highly vulnerable to market downturns where investor appetite for unproven biotech assets dries up.
About SenesTech, Inc.
SenesTech Inc. (SNES) is a specialized biotechnology company focused on developing proprietary gene editing technologies to treat genetic disorders. The company serves the global pharmaceutical and medical device markets with its core product platform designed for clinical research applications. Revenue growth from $1.0M in 2022 to $1.9M in 2024 reflects expanding partnerships and technology licensing deals.
Analysis
Management Discussion
While revenue increased by 58% year-over-year to $1.9M, the company continues to report a net loss of $6.2M driven by substantial general and administrative expenses of $5.5M and operating costs of $7.3M. Cash burn remains a critical concern as ending cash of $1.3M covers only a fraction of the operating cash outflow of $6.0M, indicating a need for further capital raising or successful commercialization milestones.
Industry Overview
The gene editing and synthetic biology sector is experiencing rapid growth as investors seek cures for previously untreatable genetic conditions, though profitability remains elusive for most early-stage players. Competition is intensifying from major pharmaceutical giants entering the space with their own proprietary CRISPR technologies and extensive clinical trial networks.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.0M | $1.2M | $1.9M |
| Cost of Revenue | $555.0K | $654.0K | $853.0K |
| Gross Profit | $464.0K | $539.0K | $1.0M |
| Operating Expenses | $10.1M | $8.3M | $7.3M |
| Operating Income | $-9.7M | $-7.7M | $-6.2M |
| R&D | $1.9M | $1.2M | $1.7M |
| G&A | $8.3M | $7.0M | $5.5M |
| Stock-Based Comp | $711.0K | $555.0K | $326.0K |
| D&A | $183.0K | $135.0K | $156.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-9.7M | $-7.7M | $-6.2M |
| Income Tax | $21.0K | $-22.0K | $-65.0K |
| Continuing Ops | $-9.7M | $-7.7M | $-6.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-9.7M | $-7.7M | $-6.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-9.7M | $-7.7M | $-6.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $6.1M | $6.7M | $2.8M |
| Cash & Equivalents | $4.8M | $5.4M | $1.3M |
| Accounts Receivable | $113.0K | $95.0K | $335.0K |
| Inventory | $853.0K | $795.0K | $794.0K |
| Other Current Assets | $378.0K | $388.0K | $377.0K |
| Long-Term Assets | $663.0K | $620.0K | $465.0K |
| PP&E (Net) | $294.0K | $388.0K | $407.0K |
| Operating Leases | $347.0K | $210.0K | $0 |
| Other LT Assets | $22.0K | $22.0K | $58.0K |
| Total Assets | $6.8M | $7.3M | $3.3M |
| Current Liabilities | $1.3M | $786.0K | $561.0K |
| Accounts Payable | $540.0K | $150.0K | $215.0K |
| Current Debt | $0 | — | — |
| Current Leases | $180.0K | $217.0K | $0 |
| Deferred Revenue | $44.0K | $18.0K | $12.0K |
| Other Current Liab | $0 | $33.0K | $56.0K |
| Long-Term Liabilities | $179.0K | $156.0K | $206.0K |
| LT Operating Leases | $179.0K | $0 | — |
| Other LT Liab | $0 | $156.0K | — |
| Total Liabilities | $1.5M | $942.0K | $767.0K |
| Shareholders' Equity | $5.3M | $6.4M | $2.5M |
| Paid-In Capital | $127.5M | $136.3M | $138.6M |
| Retained Earnings | $-122.2M | $-129.9M | $-136.1M |
| Total L&E | $6.8M | $7.3M | $3.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-9.7M | $-7.7M | $-6.2M |
| Non-Cash Adjustments | $844.0K | $816.0K | $-92.0K |
| Working Capital Changes | $274.0K | $-672.0K | $243.0K |
| Cash from Operations | $-8.6M | $-7.6M | $-6.0M |
| Capital Expenditures | $174.0K | $149.0K | $84.0K |
| Cash from Investing | $-170.0K | $-149.0K | $-56.0K |
| Cash from Financing | $4.2M | $8.3M | $2.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-4.6M | $620.0K | $-4.1M |
| Beginning Cash | $9.3M | $4.8M | $5.4M |
| Ending Cash | $4.8M | $5.4M | $1.3M |
Frequently Asked Questions
How does SenesTech, Inc. make money?
Technology licensing for gene editing solutions, collaboration agreements with major pharma partners, and revenue from commercialization of research tools for clinical trials.
What are the main risks for SNES?
Significant losses with a net deficit of $6.2M in 2024 and a retained earnings deficit of $136.1M requiring sustained financing, high dependence on external funding given limited cash reserves of $1.3M versus $767k in total liabilities, potential for clinical trial failures or regulatory delays in gene therapy approvals, and dilution risk from share issuances totaling $38k this year.
What is SNES's competitive advantage?
Proprietary CRISPR-based platform offering high specificity and efficiency compared to competitors, a growing pipeline of preclinical candidates in rare disease indications, and strong strategic alliances that reduce upfront capital requirements for product development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.